Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy.

Kaboli, Parham Jabbarzadeh; Imani, Saber; Jomhori, Masume; Ling, King-Hwa

Kaboli, Parham Jabbarzadeh; Imani, Saber; Jomhori, Masume; Ling, King-Hwa.

Afiliación

Kaboli PJ; Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University Taichung 404, Taiwan.
Imani S; Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia Serdang, Selangor 43400, Malaysia.
Jomhori M; Department of Oncology, The Affiliated Hospital of Southwest Medical University Luzhou, Sichuan 646000, P. R. China.
Ling KH; Department of Biotechnology Research, Razi Vaccine and Serum Research Institute Mashhad, Iran.

Am J Cancer Res ; 11(10): 5155-5183, 2021.

Article en En | MEDLINE | ID: mdl-34765318

Palabras clave

PI3K/Akt/mTOR inhibitor; breast cancer; drug resistance; stress conditions; targeted therapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Cancer Res Año: 2021 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google